PHARNEXT (EPA:ALPHA) Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
Transparency directive : regulatory news
31/03/2021 12:29